Interplay between Clonal Hematopoiesis of Indeterminate Potential and Metabolism

Trends Endocrinol Metab. 2020 Jul;31(7):525-535. doi: 10.1016/j.tem.2020.02.005. Epub 2020 Mar 3.

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP), defined as a clone of hematopoietic cells consisting of a single acquired mutation during a lifetime, has recently been discovered to be a major risk factor for atherosclerotic cardiovascular disease (CVD). As such, this phenomenon has sparked interest into the role that these single mutations may play in CVD. Atherosclerotic CVD is a complex disease and we have previously shown that atherosclerosis can be accelerated by metabolic- or autoimmune-related risk factors such as diabetes, obesity, and rheumatoid arthritis. In this review, we discuss the role of CHIP, the interplay between CHIP and metabolic diseases, as well as how metabolism of hematopoietic stem cells (HSCs) could regulate CHIP-related HSC fate.

Keywords: cardiovascular disease; clonal hematopoiesis of indeterminant potential; diabetes; inflammation; metabolism.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular Diseases / physiopathology*
  • Clonal Hematopoiesis / genetics
  • Clonal Hematopoiesis / physiology*
  • Diabetes Mellitus / metabolism*
  • Diabetes Mellitus / physiopathology*
  • Humans
  • Mutation / genetics